...other biotechs -- diabetic cardiomyopathy and metabolic company Applied Therapeutics Inc. (NASDAQ:APLT) and pruritus company Trevi Therapeutics Inc....
...a Phase IIb/III study of pruritus therapy nalbuphine ER scheduled to read out next year, Trevi Therapeutics Inc.... ...OPRK1) - κ opioid receptor; MOR (OPRM1) - μ opioid receptor
Paul Bonanos, Assistant Editor
Nalbuphine ER (T111)
Trevi Therapeutics Inc....
...On July 20, dermatology play Trevi Therapeutics Inc. (New Haven, Conn.) raised $50.5 million in a series C... ...see BioCentury, Sept. 14, 2015 ). Trevi Therapeutics Inc. , New Haven, Conn.
Mary Romeo
T111
Menlo Therapeutics Inc.
New Enterprise Associates
Sanofi
Trevi Therapeutics Inc.
Kappa...
...other biotechs -- diabetic cardiomyopathy and metabolic company Applied Therapeutics Inc. (NASDAQ:APLT) and pruritus company Trevi Therapeutics Inc....
...a Phase IIb/III study of pruritus therapy nalbuphine ER scheduled to read out next year, Trevi Therapeutics Inc.... ...OPRK1) - κ opioid receptor; MOR (OPRM1) - μ opioid receptor
Paul Bonanos, Assistant Editor
Nalbuphine ER (T111)
Trevi Therapeutics Inc....
...On July 20, dermatology play Trevi Therapeutics Inc. (New Haven, Conn.) raised $50.5 million in a series C... ...see BioCentury, Sept. 14, 2015 ). Trevi Therapeutics Inc. , New Haven, Conn.
Mary Romeo
T111
Menlo Therapeutics Inc.
New Enterprise Associates
Sanofi
Trevi Therapeutics Inc.
Kappa...